Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Servier
Servier
Eli Lilly and Company
Instituto do Cancer do Estado de São Paulo
National Cancer Institute (NCI)
Alliance for Clinical Trials in Oncology
Turning Point Therapeutics, Inc.
AstraZeneca
Sotio Biotech Inc.
Pfizer
Pfizer
M.D. Anderson Cancer Center
Stanford University
Erasca, Inc.
Sichuan Enray Pharmaceutical Sciences Company
Arvinas Inc.
University of Colorado, Denver
xCures
University of Nebraska
Zhejiang University
Adela, Inc
Eli Lilly and Company
RenJi Hospital
Degron Therapeutics Co.
Bayer
Actym Therapeutics, Inc.
Merck Sharp & Dohme LLC
Ikena Oncology
Eli Lilly and Company
Washington University School of Medicine
Sensei Biotherapeutics, Inc.
Jonsson Comprehensive Cancer Center
Sichuan Enray Pharmaceutical Sciences Company
Azienda Ospedaliera di Padova
Apollomics Inc.
ModeX Therapeutics, An OPKO Health Company
TransThera Sciences (Nanjing), Inc.
Hoffmann-La Roche
Columbia University